MTD of decitabine and vorinostat, determined according to incidence of DLT graded using NCI CTCAE version 4.0 28 days [clinicaltrials_resource:73041ab833e209b7b78e5057fcd21315]
INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; oral vorinostat on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.
MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
MTD of decitabine and vorinostat, determined according to incidence of DLT graded using NCI CTCAE version 4.0 28 days [clinicaltrials_resource:73041ab833e209b7b78e5057fcd21315]
INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; oral vorinostat on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.
MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
73041ab833e209b7b78e5057fcd21315
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:73041ab833e209b7b78e5057fcd21315
measure [clinicaltrials_vocabulary:measure]
MTD of decitabine and vorinost ...... ed using NCI CTCAE version 4.0
time frame [clinicaltrials_vocabulary:time-frame]
description
INDUCTION THERAPY: Patients re ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:73041ab833e209b7b78e5057fcd21315
title
MTD of decitabine and vorinost ...... NCI CTCAE version 4.0 28 days
@en
type
label
MTD of decitabine and vorinost ...... 41ab833e209b7b78e5057fcd21315]
@en